Mirikizumab and Tirzepatide Trial
Phase 3
350
about 2.8 years
18–70
37 sites in AL, CA, FL +20
About this study
Researchers are testing whether a combination of mirikizumab and tirzepatide, compared to mirikizumab alone, helps reduce or eliminate symptoms of ulcerative colitis (UC) in adults with UC and obesity. The trial will last up to 61 weeks, including 52 weeks of treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Mirikizumab
- 2.Take Placebo
- 3.Take Tirzepatide
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
mirikizumab, tirzepatide
injection (Injection)
Secondary: Percentage of Participants Who Achieve Bowel Movement Urgency Improvement Captured with Urgency Numeric Rating Scale (NRS)
Endocrinology, Gastroenterology